Taken together, the continuation of IM-based therapy for IM-resistant GISTs might have a negative impact and facilitate disease progression via the promotion of GIST malignant behavior in an FGF2-dependent manner. The gene discussed is FGF2; the disease is gastrointestinal stromal tumor.